These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 25956383)

  • 1. Effect of Device Design and Formulation on the In Vitro Comparability for Multi-Unit Dose Dry Powder Inhalers.
    Shur J; Saluja B; Lee S; Tibbatts J; Price R
    AAPS J; 2015 Sep; 17(5):1105-16. PubMed ID: 25956383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preparation and Evaluation of Surface Modified Lactose Particles for Improved Performance of Fluticasone Propionate Dry Powder Inhaler.
    Singh DJ; Jain RR; Soni PS; Abdul S; Darshana H; Gaikwad RV; Menon MD
    J Aerosol Med Pulm Drug Deliv; 2015 Aug; 28(4):254-67. PubMed ID: 25517187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of device design on the in vitro performance and comparability for capsule-based dry powder inhalers.
    Shur J; Lee S; Adams W; Lionberger R; Tibbatts J; Price R
    AAPS J; 2012 Dec; 14(4):667-76. PubMed ID: 22723022
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Formulation of novel dry powder inhalation for fluticasone propionate and salmeterol xinafoate with capsule-based device.
    Kim KS; Kim JH; Jin SG; Kim DW; Kim JO; Yong CS; Youn YS; Oh KT; Woo JS; Choi HG
    Pharm Dev Technol; 2018 Feb; 23(2):158-166. PubMed ID: 28612675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic effect of magnesium stearate and fine lactose in improving aerosolization performance of fluticasone propionate in dry powder formulation.
    He X; Li J; Wen X; Ma S; An Y; Zhang X; Guan J; Mao S
    Int J Pharm; 2024 Oct; 664():124609. PubMed ID: 39163928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The influence of secondary processing on the structural relaxation dynamics of fluticasone propionate.
    Depasquale R; Lee SL; Saluja B; Shur J; Price R
    AAPS PharmSciTech; 2015 Jun; 16(3):589-600. PubMed ID: 25398478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Agglomerate behaviour of fluticasone propionate within dry powder inhaler formulations.
    Le VN; Robins E; Flament MP
    Eur J Pharm Biopharm; 2012 Apr; 80(3):596-603. PubMed ID: 22198291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigation into the influence of primary crystallization conditions on the mechanical properties and secondary processing behaviour of fluticasone propionate for carrier based dry powder inhaler formulations.
    Kubavat HA; Shur J; Ruecroft G; Hipkiss D; Price R
    Pharm Res; 2012 Apr; 29(4):994-1006. PubMed ID: 22161310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insights into the roles of carrier microstructure in adhesive/carrier-based dry powder inhalation mixtures: Carrier porosity and fine particle content.
    Shalash AO; Molokhia AM; Elsayed MM
    Eur J Pharm Biopharm; 2015 Oct; 96():291-303. PubMed ID: 26275831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dry powder inhaler device influence on carrier particle performance.
    Donovan MJ; Kim SH; Raman V; Smyth HD
    J Pharm Sci; 2012 Mar; 101(3):1097-107. PubMed ID: 22095397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coupled in silico platform: Computational fluid dynamics (CFD) and physiologically-based pharmacokinetic (PBPK) modelling.
    Vulović A; Šušteršič T; Cvijić S; Ibrić S; Filipović N
    Eur J Pharm Sci; 2018 Feb; 113():171-184. PubMed ID: 29054499
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Formulating powder-device combinations for salmeterol xinafoate dry powder inhalers.
    Hassoun M; Ho S; Muddle J; Buttini F; Parry M; Hammond M; Forbes B
    Int J Pharm; 2015 Jul; 490(1-2):360-7. PubMed ID: 25987210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Formulation pre-screening of inhalation powders using computational atom-atom systematic search method.
    Ramachandran V; Murnane D; Hammond RB; Pickering J; Roberts KJ; Soufian M; Forbes B; Jaffari S; Martin GP; Collins E; Pencheva K
    Mol Pharm; 2015 Jan; 12(1):18-33. PubMed ID: 25380027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dry powder inhalers: mechanistic evaluation of lactose formulations containing salbutamol sulphate.
    Kaialy W; Ticehurst M; Nokhodchi A
    Int J Pharm; 2012 Feb; 423(2):184-94. PubMed ID: 22197772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interaction of Formulation and Device Factors Determine the In Vitro Performance of Salbutamol Sulphate Dry Powders for Inhalation.
    Muddle J; Murnane D; Parisini I; Brown M; Page C; Forbes B
    J Pharm Sci; 2015 Nov; 104(11):3861-3869. PubMed ID: 26220184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dry powder inhalers: the influence of device resistance and powder formulation on drug and lactose deposition in vitro.
    Srichana T; Martin GP; Marriott C
    Eur J Pharm Sci; 1998 Dec; 7(1):73-80. PubMed ID: 9845780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Air classifier technology (ACT) in dry powder inhalation Part 4. Performance of air classifier technology in the Novolizer multi-dose dry powder inhaler.
    de Boer AH; Hagedoorn P; Gjaltema D; Goede J; Frijlink HW
    Int J Pharm; 2006 Mar; 310(1-2):81-9. PubMed ID: 16442246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro dry powder inhaler formulation performance considerations.
    Ziffels S; Bemelmans NL; Durham PG; Hickey AJ
    J Control Release; 2015 Feb; 199():45-52. PubMed ID: 25497311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predicting the behavior of novel sugar carriers for dry powder inhaler formulations via the use of a cohesive-adhesive force balance approach.
    Hooton JC; Jones MD; Price R
    J Pharm Sci; 2006 Jun; 95(6):1288-97. PubMed ID: 16637052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of capsule type on aerodynamic performance of inhalation products: A case study using a formoterol-lactose binary or ternary blend.
    Wauthoz N; Hennia I; Ecenarro S; Amighi K
    Int J Pharm; 2018 Dec; 553(1-2):47-56. PubMed ID: 30321640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.